Our roots are in one of America’s great entrepreneurial success stories. Fidelity Investments was founded in 1946 and grew from a single mutual fund into one of the largest asset management firms in the world, with over $2 trillion in assets under management. For the last forty years, our venture capital group has had the privilege of backing other great entrepreneurs as they built ground-breaking companies in technology and life sciences, including Atari, MCI, ROLM Corp., Alibaba, Ironwood Pharmaceuticals, and Ultragenyx.

Today our funds are larger and more global, but our teams are still small and local. We stay true to our entrepreneurial roots. In the US and Europe, we are F-Prime Capital investing in healthcare (formerly Fidelity Biosciences) and in technology (formerly part of Devonshire Investors). In other geographies, our sister fund is called Eight Roads (formerly Fidelity Growth Partners), with investment teams in London, Shanghai, Beijing, Hong Kong, Tokyo, and Mumbai. Together we bring a world of insight, domain expertise and relationships to support our entrepreneurs. Without the pressure of fundraising from outside investors, we focus all of our time finding and helping great entrepreneurs build important companies.

Show more
TypeInvestor
HQCambridge, US
Founded1946
Websitefprimecapital.com
F-Prime Capital Partners was founded in 1946 and is headquartered in Cambridge, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at F-Prime Capital Partners

Mary Pendergast Bevelock

Mary Pendergast Bevelock

CFO
David Jegen

David Jegen

Partner
Jenny Rooke

Jenny Rooke

Venture Partner
Jessica Alston

Jessica Alston

Associate
Show more

F-Prime Capital Partners Office Locations

F-Prime Capital Partners has an office in Cambridge
Cambridge, US (HQ)
1 Main St
Show all (1)
Report incorrect company information

F-Prime Capital Partners News and Updates

Akrevia Therapeutics Launches with $30M Series A Financing Led by F-Prime Capital Partners and Atlas Venture

CAMBRIDGE, Mass., Sept. 27, 2018 /PRNewswire/ -- Akrevia Therapeutics, a privately-held biopharmaceutical company focused on developing highly-potent, tumor-targeted immuno-oncology therapeutics, today announced the closing of a $30 million Series A financing led by F-Prime Capital...
Report incorrect company information

F-Prime Capital Partners Company Life and Culture

Report incorrect company information